



Concord Medical Receives Singapore MOH Approval of New Name and Operation of Concord Cancer Hospital

October 14, 2015

BEIJING, Oct. 14, 2015 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced the Company has received approval from the Singapore Ministry of Health to change the name of the Fortis Surgical Hospital, which was acquired by the Company in April, to Concord Cancer Hospital. Concord Cancer Hospital in Singapore will provide oncology as its main services, including medical oncology and surgical oncology. Concord Cancer Hospital will offer a number of treatment options for patients including cancer screening, diagnosis, cancer prevention services, chemotherapy and post-chemotherapy follow up, and palliative care for end stage cancer. Using Da Vinci Robotic Surgical System, the hospital also provides minimal invasive surgery on patients with colorectal cancer, urology, gynaecology and other cancer sites.

The company plans to establish a close partnership with MD Anderson in the operation of Concord Cancer Hospital. According to the Clinical and Quality Management Program Development Agreement signed between the company and University of Texas MD Anderson Cancer Center on April 1, 2015, MD Anderson will assist and support Concord Cancer Hospital to develop and implement the clinical quality and patient safety processes necessary for the hospital to qualify for the Associate Member Program of MD Anderson.

Currently, the Company is undergoing necessary equipment and internal refurbishment in order to offer high-quality services to patients in Asian area, who will receive MDACC-standard treatment and services in the state-of-the-art facility.

About Concord Medical

Concord Medical Services Holdings Limited is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China. As of June 30, 2015, the Company operated a network of 129 centers with 76 hospital partners that spanned 53 cities and 25 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. As part of its high-end cancer hospital development strategy and oversea business extension, the Company acquired Fortis Surgical Hospital, a private hospital in Singapore in April, 2015. For more information, please see <http://ir.concordmedical.com>.

For investor and media inquiries please contact:

Concord Medical Services

Mr. Adam J. Sun (Chinese and English)
+86 10 5957 5266
adam.sun@concordmedical.com

Ms. Fang Liu (Chinese and English)
+86 10 5903 6688 (ext. 639)
fang.liu@concordmedical.com

ICR Inc.

Mr. William Zima
+1 203-682-8233
William.Zima@icrinc.com

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/concord-medical-receives-singapore-moh-approval-of-new-name-and-operation-of-concord-cancer-hospital-300159443.html>

SOURCE Concord Medical Services Holdings Limited